Upstream Bio (NASDAQ:UPB) Trading Down 7.3% – Here’s Why

Upstream Bio, Inc. (NASDAQ:UPBGet Free Report)’s share price fell 7.3% during trading on Tuesday . The stock traded as low as $9.30 and last traded at $9.15. 7,240 shares changed hands during mid-day trading, a decline of 98% from the average session volume of 325,232 shares. The stock had previously closed at $9.87.

Upstream Bio Price Performance

The business has a 50-day moving average price of $9.62.

Hedge Funds Weigh In On Upstream Bio

A number of large investors have recently bought and sold shares of UPB. Moody Aldrich Partners LLC purchased a new stake in shares of Upstream Bio during the 4th quarter valued at $1,229,000. Rhumbline Advisers purchased a new stake in Upstream Bio during the fourth quarter valued at about $275,000. Bank of New York Mellon Corp acquired a new stake in Upstream Bio during the fourth quarter worth about $607,000. US Bancorp DE purchased a new position in shares of Upstream Bio in the 4th quarter worth about $27,000. Finally, Charles Schwab Investment Management Inc. acquired a new position in shares of Upstream Bio in the 4th quarter valued at about $2,225,000.

About Upstream Bio

(Get Free Report)

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.

See Also

Receive News & Ratings for Upstream Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Upstream Bio and related companies with MarketBeat.com's FREE daily email newsletter.